Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection.

IF 3.4

Diabetes & metabolic syndrome Pub Date : 2020-11-01 Epub Date: 2020-08-26 DOI:10.1016/j.dsx.2020.08.023

Timotius Ivan Hariyanto, Andree Kurniawan

{"title":"Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection.","authors":"Timotius Ivan Hariyanto, Andree Kurniawan","doi":"10.1016/j.dsx.2020.08.023","DOIUrl":null,"url":null,"abstract":"Background and aims: The coronavirus disease 2019 (COVID-19) number of death cases is still increasing. One of the comorbidities associated with severe outcome and mortality of COVID-19 is dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of dyslipidemic patients. This study aims to analyze the association between statin use and in-hospital outcomes of COVID-19 infection.Methods: We systematically searched the Google Scholar database using specific keywords related to our aims until August 1st, 2020. All articles published on COVID-19 and statin were retrieved. Statistical analysis was done using Review Manager 5.4 software.Results: A total of 9 studies with a total of 3449 patients were included in our analysis. Our meta-analysis showed that statin use did not improve severity outcome [OR 1.64 (95% CI 0.51-5.23), p = 0.41, I2 = 93%, random-effect modelling] nor mortality rate from COVID-19 infection [OR 0.78 (95% CI 0.50-1.21), p = 0.26, I2 = 0%, fixed-effect modelling].Conclusion: Statin use did not improve in-hospital outcomes of COVID-19 infections. Patients with dyslipidemia should continue taking statin drugs despite COVID-19 infection status, given its beneficial effects on cardiovascular outcomes.","PeriodicalId":520602,"journal":{"name":"Diabetes & metabolic syndrome","volume":" ","pages":"1613-1615"},"PeriodicalIF":3.4000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dsx.2020.08.023","citationCount":"76","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolic syndrome","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.dsx.2020.08.023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/8/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 76

Abstract

Background and aims: The coronavirus disease 2019 (COVID-19) number of death cases is still increasing. One of the comorbidities associated with severe outcome and mortality of COVID-19 is dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of dyslipidemic patients. This study aims to analyze the association between statin use and in-hospital outcomes of COVID-19 infection.

Methods: We systematically searched the Google Scholar database using specific keywords related to our aims until August 1st, 2020. All articles published on COVID-19 and statin were retrieved. Statistical analysis was done using Review Manager 5.4 software.

Results: A total of 9 studies with a total of 3449 patients were included in our analysis. Our meta-analysis showed that statin use did not improve severity outcome [OR 1.64 (95% CI 0.51-5.23), p = 0.41, I² = 93%, random-effect modelling] nor mortality rate from COVID-19 infection [OR 0.78 (95% CI 0.50-1.21), p = 0.26, I² = 0%, fixed-effect modelling].

Conclusion: Statin use did not improve in-hospital outcomes of COVID-19 infections. Patients with dyslipidemia should continue taking statin drugs despite COVID-19 infection status, given its beneficial effects on cardiovascular outcomes.

Abstract Image

查看原文本刊更多论文

他汀类药物治疗并没有改善2019冠状病毒病(COVID-19)感染的住院结果。

背景与目的:2019冠状病毒病(COVID-19)死亡病例数仍在增加。与COVID-19严重结局和死亡率相关的合并症之一是血脂异常。他汀类药物是最常用于治疗血脂异常患者的药物之一。本研究旨在分析他汀类药物使用与COVID-19感染住院结局之间的关系。方法:我们使用与我们的目标相关的特定关键词系统地检索Google Scholar数据库，直到2020年8月1日。检索所有发表的关于COVID-19和他汀类药物的文章。采用Review Manager 5.4软件进行统计分析。结果:我们的分析共纳入9项研究，共3449例患者。我们的荟萃分析显示，他汀类药物的使用并没有改善重症结局[OR 1.64 (95% CI 0.51-5.23)， p = 0.41, I2 = 93%，随机效应模型]，也没有改善COVID-19感染的死亡率[OR 0.78 (95% CI 0.50-1.21)， p = 0.26, I2 = 0%，固定效应模型]。结论:他汀类药物的使用并未改善COVID-19感染的住院结果。鉴于他汀类药物对心血管预后的有益影响，血脂异常患者应继续服用他汀类药物，尽管他们感染了COVID-19。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & metabolic syndrome

自引率

0.00%

发文量